The screening programs at Myto Health have discovered several inhibitors and activators of mitophagy from small molecules libraires and optimized medicinal chemistry approaches. We have also screened several natural product libraries to discover activators (nutraceuticals) that promote mitophagy and mitobiogenesis. Mitophagy and mitobiogenesis are initiated by ubiquitin proteasome system (UPS).  Myto Health has also established a diagnostic platform to monitor poly-ubiquitin signatures from human blood as biomarkers for diseases, with a focus on Parkinson’s disease. Myto Health has compiled a list of mutations in UPS enzymes that result in early and late onset PD. The structure of mutated enzyme and its relationship to function and pathology of PD has allowed Myto Health to establish an artificial intelligence platform which Patients and providers can use to evaluate their predisposition to neurodegenerative diseases through inputting their genomic DNA sequence. Myto Health’s overall platform allows discovery and development of drugs, nutraceuticals, and diagnostic tools to monitor susceptibility to neurodegeneration and help clinicians to select a patient population that responds to UPS mitochondrial targeting therapies (personalized medicine).